Unique ID issued by UMIN | UMIN000027985 |
---|---|
Receipt number | R000032049 |
Scientific Title | Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: Feasibility study |
Date of disclosure of the study information | 2017/07/31 |
Last modified on | 2017/08/01 09:34:22 |
Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: Feasibility study
Feasibility Study of nivolumab maintenance therapy
Nivolumab maintenance as monotherapy after carboplatine plus nab-paclitaxel for first-line treatment of advanced Non-small-cell lung cancer: Feasibility study
Feasibility Study of nivolumab maintenance therapy
Japan |
Non-Small Cell Lung Cancer
Pneumology |
Malignancy
NO
To determine recommended dose and cycles of carboplatine plus nab-paclitaxel for nivolumab maintenance therapy in non-small-cell lung cancer
Safety
Exploratory
Phase I
Feasibility of nivolumab maintenance therapy after carboplatine plus nab-paclitaxel
Anti-tumor efficacy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Level 1:carboplatin AUC 6+nab-paclitaxel,4cycles
Level 0:carboplatin AUC 5+nab-paclitaxel,3cycles
If 3 or more of the first 6 patients who had been originally allocated to the level 1 experienced nivolumab-induced grade 3-4 toxicity, additinal 6 patients were enrolled to the level 0. If 2 or less of the first 6 patients in level 1 who had experienced nivolumab-induced grade 3-4 toxicity,additinal 6 patients were enrolled to the level 1.
20 | years-old | <= |
80 | years-old | > |
Male and Female
1)Histology/cytology-proven non-small cell lung cancer
2)No prior treatment
3)Stage IIIB, IV and unsuitable for radiotherapy
4)EGFR(-),ALK(-)
5)PD-L1 staining:1%-49%
6)With one or more measurable disease based on RECIST
7)Performance status(ECOG): 0-1
8)Age 20<80
9)Adequate organ function
10)Written informed consent
1) Interstitial pneumonia/lung fibrosis on chest X-ray
2) History of chest radiation therapy
3) Auto-immuno disease patients
4) Receiving steroid therapy
5) Symptomatic brain metastasis
6) Active hepatic disease
7) Having serious complications
8) Uncontrolled ascites, pleural effusion or cardiac effusion
9) History of multiple malignancies within 3 years
10) Planning of surgery during the trial
11) A pregnant woman, a nursing girl and woman with the possibility (intention) of the pregnancy, and
12) Having serious mental disorder
13) Previous drug allergy
14) Those judged to be not suitable by the attending physician
12
1st name | |
Middle name | |
Last name | Masao Ichiki |
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
092-852-0700
ichiki@kyumed.jp
1st name | |
Middle name | |
Last name | Masao Ichiki |
National Hospital Organization Kyushu Medical Center
Department of Respiratory Medicine
1-8-1 Jigyohama Chuo-ku, Fukuoka 810-8563, Japan
092-852-0700
ichiki@kyumed.jp
National Hospital Organization Kyushu Medical Center,Department of Respiratory Medicine
National Hospital Organization Kyushu Medical Center,Department of Respiratory Medicine
Other
NO
2017 | Year | 07 | Month | 31 | Day |
Unpublished
Open public recruiting
2017 | Year | 06 | Month | 28 | Day |
2017 | Year | 08 | Month | 01 | Day |
2017 | Year | 06 | Month | 28 | Day |
2017 | Year | 08 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032049
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |